Evaluate pelvic recurrent rate and survival outcome in stage III-IVA endometrial cancer who receive adjuvant chemotherapy plus radiation versus chemotherapy alone endometrial cancer radiation adjuvant treatment
Conditions
Interventions
No Intervention No treatment,Active Comparator Radiation,Active Comparator Radiation
chemotherapy alone,Chemotherapy plus VBT,Chemotherapy plus EBRT plus VBT
chemotherapy 6 cycles,HDR brachytherapy 7 Gy, 3 F after chemotherapy 6 cycles
,WPRT 44-45 Gy, 20-25 F after chemotherapy 6 cycles
plus VBT 5.5 Gy, 2 F if pathological report has cervical stromal invas
Sponsors
Mahidol University
Eligibility
Sex/Gender
Female
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Participants must be 18 years of age or older. 2. Participants must have been diagnosed with stage III-IVA endometrial cancer through surgical staging at Siriraj Hospital. 3. Participants must not have any suspicious pathological lymph nodes on radiographic imaging (CT scan, MRI, or PET scan) following chemotherapy.
Exclusion criteria
Exclusion criteria: 1. Participants who have progression of disease of during or after receiving chemotherapy. 2. Participants who develop secondary cancer while participating in the research study. 3. Participants who have previously received radiation therapy to the pelvic area.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pelvic recurrence 24 months after intervention physical examination, CT scan | — |
Secondary
| Measure | Time frame |
|---|---|
| extra pelvic recurrence 24 months after intervention physical examination, CT scan | — |
Countries
Thailand
Contacts
Public ContactKhemanat Khemworapong
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed